Business Context and Reporting Period
Company: Passage BIO, Inc. (PASG)
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2025 (Earliest event reported)
Reporting Period: Updates reflect events as of January 8, 2025, and financial positions as of December 31, 2024.
Key Financial Metrics
- Liquidity: Preliminary, unaudited cash, cash equivalents, and marketable securities position as of December 31, 2024, is approximately $76.8 million.
- Cash Runway: Management expects current liquidity to fund operating expenses and capital expenditures into the first quarter of 2027.
- Restructuring Costs: Estimated aggregate severance and exit costs of approximately $2.0 million, primarily recorded in Q1 2025.
- Asset Impairment: Expected non-cash impairment expenses for laboratory equipment ranging from $1.0 million to $3.0 million in Q1 2025.
- Cost Savings: The restructuring plan is expected to decrease annual operating costs by approximately $9.0 million to $11.0 million.
Material Changes and Restructuring Plan
On January 8, 2025, the Board approved a Restructuring Plan to align the workforce with strategic R&D needs and cease lab operations at its 62,000 square foot facility in Hopewell, New Jersey.
- Workforce Reduction: Overall workforce reduction of approximately 55%.
- Implementation Timeline: Substantially complete by the end of Q1 2025.
- Asset Disposal: The Company is pursuing subleasing opportunities for the laboratory space and selling laboratory equipment to offset financial obligations.
Outlook, Management Commentary, and Clinical Updates
PBFT02 Program (Frontotemporal Dementia):
- Biomarkers: Dose 1 treatment resulted in robust, durable increases in progranulin (PGRN) expression in cerebrospinal fluid (CSF). CSF PGRN levels plateaued by month 6 and remained durable through 18 months in one patient.
- Safety: In five of seven patients, adverse events were mild to moderate. Two patients experienced serious adverse events (venous sinus thrombosis and hepatotoxicity), leading to a revised immunosuppression regimen for subsequent patients. No evidence of dorsal root ganglion toxicity was observed.
- Manufacturing: Successfully completed process development and scale-up of an improved-productivity, suspension-based manufacturing process.
Anticipated Milestones:
- Evaluate Dose 2 (50% lower than Dose 1) in FTD-GRN and FTD-C9orf72 patients.
- Report 12-month Dose 1 data and interim Dose 2 data in H2 2025.
- Initiate dosing of FTD-C9orf72 patients in H1 2025.
- Seek regulatory feedback on FTD-GRN registrational trial design in H1 2026.
Investor Verification Checklist
- Verify the final audited cash position as of December 31, 2024, against the preliminary $76.8 million figure.
- Monitor the actual execution of the 55% workforce reduction and the timing of the $2.0 million severance expense recognition in Q1 2025.
- Track the progress of subleasing the Hopewell, NJ facility and the sale of equipment to determine if additional impairments beyond the $1.0–$3.0 million estimate are required.
- Confirm the safety profile of the revised immunosuppression regimen in upcoming Dose 2 patients.
- Validate the timeline for initiating FTD-C9orf72 dosing in the first half of 2025.